Ana Ruiz-Garcı́a

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

Sandrine Faivre, Éric Raymond, Éveline Boucher et al. · The Lancet Oncology · 2009 · 288 citations

Hepatology, Medicine, Pharmacology +8

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Suresh S. Ramalingam, Fiona Blackhall, Maciej Krzakowski et al. · Journal of Clinical Oncology · 2012 · 265 citations · Full text

PAMPA—a drug absorption in vitro model

Marival Bermejo, Alex Avdeef, Ana Ruiz-Garcı́a et al. · European Journal of Pharmaceutical Sciences · 2004 · 203 citations

Pharmacological Study, Medicine, Pampa—a Drug Absorption +4

Phase II study of sunitinib as second-line treatment for advanced gastric cancer

Yung‐Jue Bang, Yoon‐Koo Kang, Won Ki Kang et al. · Investigational New Drugs · 2010 · 193 citations · Full text

A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

Karen L. Reckamp, Giuseppe Giaccone, D. Ross Camidge et al. · Cancer · 2014 · 142 citations · Full text